CYP3A4, CYP3A5, and CYP4F2 Polymorphisms and Bleeding Risk in Ticagrelor-Based Dual Antiplatelet Therapy.

Multiple clinical and genetic predictors were evaluated without correction for multiple comparisons; the analyses are therefore exploratory, and the single nominally significant genetic association in the cohort, univariable CYP3A5 *1 carrier status ( p = 0.043), would not survive correction for the number of predictors tested and should be regarded as hypothesis-generating.

also in 7,732 other papers